Drug misuse and diversion in adults prescribed anxiolytics and sedatives

Pharmacotherapy

Volumn 31, Issue 3, 2011, Pages 262-272

  McLarnon, Megan E ^a   Monaghan, Tracy L ^a   Stewart, Sherry H ^a   Barrett, Sean P ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anxiolytics; Benzodiazepines; Drug diversion; Prescription drug misuse; Sedatives

Indexed keywords

ANXIOLYTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; FEMALE; HOPELESSNESS; HUMAN; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RECOMMENDED DRUG DOSE; SUBSTANCE ABUSE; TREATMENT DURATION;

ADULT; ANTI-ANXIETY AGENTS; CANADA; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79952429355     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.3.262     Document Type: Article

References (62)

1. Busto UE. Benzodiazepines: the science and the myths. Can J Clin Pharmacol 1999;6:185-6. (Pubitemid 30015581)
2. Nowell PD, Mazumdar S, Buysse DJ, Dew A, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7. (Pubitemid 28013492)
3. O'Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005;66(suppl 2):28-33. (Pubitemid 40343678)
4. Romach M, Busto U, Somer G, Kaplan HL, Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry 1995;152:1161-7.
5. Hertz JA, Knight JR. Prescription drug misuse: a growing national problem. Adolesc Med 2006;17:751-69. (Pubitemid 44499165)
6. Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend 2007;90:280-7. (Pubitemid 47284722)
7. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8:45-58. (Pubitemid 34449902)
8. Stewart SA. The effect of benzodiazepines on cognition. In: Rosenbaum JF, chair. Academic highlights. Utilizing benzodiazepines in clinical practice: an evidence-based discussion. J Clin Psychiatry 2004;65:1567-8.
9. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999;9(suppl 6):S399-405.
10. Brust JCM, ed. Barbiturates and other hypnotics and sedatives. In: Neurological aspects of substance abuse. Philadelphia, PA: Butterworth Heinemann 2004:201-24.
11. Busto U, Kaplan HL, Sellers EM. Benzodiazepine-associated emergencies in Toronto. Am J Psychiatry 1999;137:224-7.
12. Coben JH, Davis SM, Furbee PM, Sikora RD, Tillotson RD, Bossarte RM. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med 2010;38:517-24.
13. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals: implications for problems of long-term use and abuse. Psychopharmacology 1997;134:1-37. (Pubitemid 27485546)
14. Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend 2007;90:252-60.
15. Riggs P. Non-medical use and abuse of commonly prescribed medications. Curr Med Res Opin 2008;24:869-77. (Pubitemid 351428998)
16. McCabe SE. Correlates of nonmedical use of prescription benzodiazepine anxiolytics: results from a national survey of U.S. college students. Drug Alcohol Depend 2005;79:53-62. (Pubitemid 41557124)
17. Boyd CJ, McCabe SE. Coming to terms with nonmedical use of prescription medications. Subst Abuse Treat Prev Policy 2008;3:22-5.
18. Farnsworth MG. Benzodiazepine abuse and dependence: misconceptions and facts. J Fam Pract 1990;31:393-400. (Pubitemid 20368558)
19. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66(suppl 9):31-41. (Pubitemid 43011561)
20. Morgan WW. Abuse liability of barbiturates and other sedative-hypnotics. Adv Alcohol Subst Abuse 1990;9:67-82. (Pubitemid 20302477)
21. Busto UE, Sellers EM. Anxiolytics and sedative/hypnotics dependence. Br J Addict 1991;86:1647-52.
22. Pollack MH. Efficacy of and concerns about benzodiazepines and their alternatives for anxiety disorders. In: Rosenbaum JF, chair. Academic highlights. Utilizing benzodiazepines in clinical practice: an evidence-based discussion. J Clin Psychiatry 2004;65:1569-71.
23. Cimolai N. Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 2007;53:2124-9.
24. Curran S, Musa S. Hypnosedatives and anxiolytics. In: Aronson JK, ed. Side effects of drugs, 25th annual report. A worldwide yearly survey of new data and trends in adverse drug reactions. Amsterdam, Netherlands: Elsevier Science, 2002:47-52.
25. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003;98:1371-8. (Pubitemid 37297243)
26. Jones IR, Sullivan G. Physical dependence on zopiclone: case reports. Br Med J 1998;316:117. (Pubitemid 28121111)
27. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 1999;144:220-33.
28. Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev 2008;1:255-62.
29. Kelly B, Parsons J. Prescription drug misuse among club drug-using young adults. Am J Drug Alcohol Abuse 2007;33:875-84. (Pubitemid 350125779)
30. McCabe SE, Boyd CJ, Teter CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006;54:269-78. (Pubitemid 43439968)
31. McCabe SE. Screening for drug abuse among medical and nonmedical users of prescription drugs in a probability sample of college students. Arch Pediatr Adolesc Med 2008;162:225-31. (Pubitemid 351342459)
32. Goodwin RD, Hasin DS. Sedative use and misuse in the United States. Addiction 2002;97:555-62. (Pubitemid 34492749)
33. Fatséas M, Lavie E, Denis C, Auriacombe M. Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients. J Subst Abuse Treat 2009;37:407-11.
34. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 2001;165:1039-44. (Pubitemid 32964866)
35. Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol Clin Exp 2007;22:529-36.
36. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-14. (Pubitemid 43675545)
37. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83S:S4-7.
38. Jaffee WB, D'Zurilla TJ. Personality, problem solving, and adolescent substance use. Behav Ther 2009;40:93-101.
39. Martin ED, Sher KJ. Family history of alcoholism, alcohol use disorders and the five-factor model of personality. J Stud Alcohol 1994;55:81-90. (Pubitemid 24006949)
40. Sher KJ, Bartholow BD, Wood MD. Personality and substance use disorders: a prospective study. J Consult Clin Psychol 2000;68:818-29.
41. Conrod PJ, Woicik P. Validation of a four-factor model of personality risk for substance abuse and examination of a brief instrument for assessing personality risk. Addict Biol 2002;7:329-46.
42. Conrod PJ, Pihl RO, Stewart SH, Dongier M. Validation of a system of classifying female substance abusers on the basis of personality and motivational risk factors for substance abuse. Psychol Addict Behav 2000;14:243-56.
43. Arria AM, Caldeira KM, Vincent KB, O'Grady KE, Wish ED. Perceived harmfulness predicts nonmedical use of prescription drugs among college students: interactions with sensation-seeking. Prev Sci 2008;9:191-201.
44. Low KG, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med 2002;7:283-7.
45. Woicik PA, Stewart SH, Pihl RO, Conrod PJ. The substance use risk profile scale: a scale measuring traits linked to reinforcement-specific substance use profiles. Addict Behav 2009;34:1042-55.
46. Barrett SP, Darredeau C, Bordy LE, Pihl RO. Characteristics of methylphenidate use in a university student sample. Can J Psychiatry 2005;50:457-61. (Pubitemid 43161798)
47. Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 2005;40:1525-37. (Pubitemid 41098807)
48. Substance Abuse and Mental Health Services Administration. Results from the 2007 national survey on drug use and health: national findings [online]. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies, NSDUH series H-34, DHHS publication no. SMA 08-4343. September 2008. Available from www.oas.samhsa.gov/nsduh.htm. Accessed January 28, 2009.
49. Repchinsky C, ed. Compendium of pharmaceuticals and specialties, 2008 edition. Ottawa, Canada: Canadian Pharmacists Association, 2008.
50. McCabe SE, Teter CJ, Boyd CJ. Illicit use of prescription pain medication among college students. Drug Alcohol Depend 2005;77:37-47. (Pubitemid 39656098)
51. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32:562-75. (Pubitemid 46038570)
52. Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. Pediatrics 2006;118;2472-80. (Pubitemid 46397588)
53. McLellan AT, Luborsky L, O'Brien CP, Wood GE. An improved diagnostic instrument for substance abuse patients: the addiction severity index. J Nerv Ment Dis 1980;168:26-33. (Pubitemid 10187569)
54. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
55. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatry 2001;58:787-94. (Pubitemid 32717805)
56. McCabe SE, Boyd CJ, Teter CJ. Subtypes of nonmedical prescription drug misuse. Drug Alcohol Depend 2009;102:63-70.
57. Statistics Canada. Visible minority population, by census metropolitan area (table). 2006 census of population. Ottawa, Canada: Industry Canada, 2007. Statistics Canada catalogue no. 92-566-XWE. Available from www41.statcan.ca/ 2009/30000/tbl/cybac30000-2009-000-t07-eng.htm. Accessed May 8, 2010.
58. Roache JD, Weisch RA. Findings from self-administration research on the addiction potential of benzodiazepines. Psychiatr Ann 1995;25:153-7.
59. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003;54:1395-401. (Pubitemid 37220041)
60. Westra HA, Stewart SH. As-needed use of benzodiazepines in managing clinical anxiety: incidence and implications. Curr Pharm Des 2002;8:59-74. (Pubitemid 34449903)
61. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend 1996;42:49-54. (Pubitemid 26300639)
62. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988;83:393-402.